Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease

Journal of Internal Medicine

Volumn 259, Issue 5, 2006, Pages 434-436

  Faergeman, O ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOCHEMICAL MARKER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; HEALTH EDUCATION; HUMAN; IMAGING; MEASUREMENT; MEDICAL PRACTICE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33645995153     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01650.x     Document Type: Conference Paper

References (22)

1. De Backer G Ambrosioni E Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003 10 S1 S10.
2. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143 421.
3. Arad Y Goodman KJ Roth M Newstein D Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. J Am Coll Cardiol 2005 46 158 65.
4. Grundy SM. Coronary plaque as a replacement for age as a risk factor in global risk assessement. Am J Cardiol 2001 88 8E 11E.
5. Stampfer MJ Sacks FM Salvini S Willett WC Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991 325 373 81.
6. Kannel WB Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992 124 768 74.
7. Walldius G Jungner I Holme I Aastveit AH Kolar W Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001 358 2026 33.
8. Yusuf S Hawken S Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 937 52.
9. Walldius G Jungner I. The apo B/apo A-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006 259 493 519.
10. Zambon A Brown BG Brunzell JD. Genetics of apolipoprotein B and apolipoprotein AI and premature cardiovascular disease. J Intern Med 2006 259 473 480.
11. Sniderman AD Jungner I Holme I Aastveit A Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006 259 455 461.
12. Barter P Rye KA. The rationale for using apo A-I as a clinical marker of cardiovascular risk. J Intern Med 2006 259 447 454.
13. Charlton-Menys V Durrington P. Apolipoproteins AI and B as therapeutic targets. J Intern Med 2006 259 462 472.
14. Marcovina S Packard CJ. Measurement and meaning of apolipoprotein A1 and apolipoprotein B plasma levels. J Intern Med 2006 259 437 446.
15. Baigent C Keech A Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 1267 78.
16. Sniderman AD Furberg CD Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003 361 777 80.
17. Gotto AM Jr. Whitney E Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000 101 477 84.
18. Barter PJ. Cardioprotective effects of high-density lipoproteins: the evidence strengthens. Arterioscler Thromb Vasc Biol 2005 25 1305 6.
19. Nissen SE Tsunoda T Tuzcu EM et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003 290 2292 300.
20. Brousseau ME Schaefer EJ Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004 350 1505 15.
21. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is. Circulation 2005 112 3366 7.
22. Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005 112 3368 70.